Infarction

Inequalities in the face of cardiovascular risk: women the No. 1 victims

Retrieved on: 
Thursday, March 7, 2024

BOSTON, March 7, 2024 /PRNewswire/ -- Cardiovascular disease kills one women every 33 seconds in the USA10. Yet 80% of these deaths could be avoided11 through early diagnosis and awareness of symptoms and risk factors specific to women. To help reduce this excess mortality, Withings is committed to raising awareness via an exclusive survey, and providing the means to tackle their main cause: hypertension, which accounts for the majority of cardiovascular deaths.12

Key Points: 
  • Inequalities also affect health, particularly cardiovascular health: they lead to under-diagnosis and poorer care for women, resulting in avoidable excess mortality.
  • Yet 80% of these deaths could be avoided11 through early diagnosis and awareness of symptoms and risk factors specific to women.
  • Yet 50% of women are unaware of their cardiovascular risk.13
    45.9% of American women surveyed by Withings admit to putting their loved ones' health before their own.
  • Withings and cardiovascular monitoring in women: the need for a real-life, longitudinal approach
    Monitoring cardiovascular health and hypertension involves tracking a range of biomarkers.

Serca Pharmaceuticals presents first-in-class strategy for game-changing, post heart-attack cardioprotection at the European Society of Cardiology Congress 2023

Retrieved on: 
Tuesday, August 29, 2023

OSLO, Norway, Aug. 29, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first-in-class treatment for minimising the tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today presented exciting preclinical data showcasing its novel therapeutic strategy targeting the SERCA2 complex to protect heart tissue from ischemia-reperfusion injury at the European Society of Cardiology Congress 2023, the world's largest cardiology congress, in Amsterdam, The Netherlands, 25–28 August 2023.

Key Points: 
  • The compound could be transformative in treating cardiology patients who are impacted by MI and stenting and is currently in preclinical drug development.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • For Experimental Medical Research
    For further details on the poster, please contact Tove Flem Jacobsen, or visit the Serca Pharmaceuticals website: https://sercapharmaceuticals.com/ .
  • Company representatives will also be attending the LSX Nordic Congress being held on the 10-11 October and look forward to meeting investors and potential partners.

Serca Pharmaceuticals presents first-in-class strategy for game-changing, post heart-attack cardioprotection at the European Society of Cardiology Congress 2023

Retrieved on: 
Tuesday, August 29, 2023

OSLO, Norway, Aug. 29, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first-in-class treatment for minimising the tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today presented exciting preclinical data showcasing its novel therapeutic strategy targeting the SERCA2 complex to protect heart tissue from ischemia-reperfusion injury at the European Society of Cardiology Congress 2023, the world's largest cardiology congress, in Amsterdam, The Netherlands, 25–28 August 2023.

Key Points: 
  • The compound could be transformative in treating cardiology patients who are impacted by MI and stenting and is currently in preclinical drug development.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • For Experimental Medical Research
    For further details on the poster, please contact Tove Flem Jacobsen, or visit the Serca Pharmaceuticals website: https://sercapharmaceuticals.com/ .
  • Company representatives will also be attending the LSX Nordic Congress being held on the 10-11 October and look forward to meeting investors and potential partners.

EQS-News: Affluent Medical Presents Poster on First Successful Procedure with Epygon at the 2023 CSI Conference in Frankfurt

Retrieved on: 
Wednesday, June 28, 2023

Abstract Title: TRANSCATHETER MITRAL VALVE IMPLATATION WITH THE EPYGON PROSTHESIS: FIRST-IN-HUMAN

Key Points: 
  • Abstract Title: TRANSCATHETER MITRAL VALVE IMPLATATION WITH THE EPYGON PROSTHESIS: FIRST-IN-HUMAN
    “We are excited to inform the specialist audience about the first successful procedure with our Epygon system,” said Dr. Christophe Giot, Vice President Clinical Affairs.
  • “Our device is the only biomimetic transcatheter cardiac mitral valve in development that mimics the native mitral valve and physiological blood flow.
  • The objective of the study is to evaluate the safety and efficacy of Epygon valve implantation at 30 days.
  • Affluent Medical anticipates presenting interim results from the first five patients of the Minerva pilot study at the Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in October 2023.

Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

Retrieved on: 
Monday, May 22, 2023

OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023, the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.

Key Points: 
  • OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023 , the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.
  • 13-M is a small NCE shown to have these important protein to protein interaction (PPI) characteristics with the capacity to modulate the SERCA2 Ca2+ pump.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • Without treatment, 30% of MI patients will go on to develop heart failure.

Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

Retrieved on: 
Monday, May 22, 2023

OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023, the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.

Key Points: 
  • OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023 , the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.
  • 13-M is a small NCE shown to have these important protein to protein interaction (PPI) characteristics with the capacity to modulate the SERCA2 Ca2+ pump.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • Without treatment, 30% of MI patients will go on to develop heart failure.

Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.

Retrieved on: 
Monday, April 17, 2023

Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.

Key Points: 
  • Affluent Medical : Very positive results one month after Epygon mitral heart valve implantation in a first patient.
  • Very positive outcome at one month follow-up of the patient implanted with the Epygon mitral valve.
  • Less than 4% of patients with severe heart mitral insufficiency receive surgery, according to Affluent Medical estimates.
  • It is the only biomimetic cardiac mitral valve in development, mimicking the native mitral valve and physiological blood flow.

Affluent Medical : Affluent Medical announces initial success of first clinical implantation of its Epygon mitral heart valve via minimally invasive route

Retrieved on: 
Thursday, March 16, 2023

Epygon is the only biomimetic mitral valve to restore the physiological blood vortex.

Key Points: 
  • Epygon is the only biomimetic mitral valve to restore the physiological blood vortex.
  • Rapid, 15 minutes, valve implantation procedure and early hospital discharge of the patient on day 5.
  • It is the only biomimetic cardiac mitral valve under development, mimicking the native mitral valve function and generating a physiological blood flow.
  • From initial hands-on the Epygon transcatheter device to deploying the valve inside the patient’s heart, it took me only 15 minutes.

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

Retrieved on: 
Thursday, February 16, 2023

The trial is being conducted at the Centre for Human Drug Research (“CHDR”) in Leiden, Netherlands.

Key Points: 
  • The trial is being conducted at the Centre for Human Drug Research (“CHDR”) in Leiden, Netherlands.
  • In addition, several pharmacodynamic measures believed to be associated with neuroplasticity, including both measurements of biochemical markers and electroencephalographic readings, will be recorded.
  • There will be up to 60 healthy volunteers enrolled in total, which will include both psychedelic experienced and psychedelic naïve subjects.
  • “Although DMT has been previously investigated in humans, we are breaking new ground in this study in terms of both the length of the infusion and the frequency of exposure.”

Bayer Announces First Patients Enrolled in Global Phase III Studies for Investigational Oral FXIa Inhibitor Asundexian

Retrieved on: 
Wednesday, February 8, 2023

“Additional research into the combination of FXI inhibition and antiplatelet agents is needed to explore potential treatment options for the future.”

Key Points: 
  • “Additional research into the combination of FXI inhibition and antiplatelet agents is needed to explore potential treatment options for the future.”
    “Through our OCEANIC clinical trial program, Bayer leverages decades of cardiovascular expertise to investigate a potential new class of antithrombotics and explore the potential of asundexian as an additional antithrombotic treatment option across multiple patient populations,” 1-2 said Maria Borentain, M.D., Vice President and Head of Thrombosis and Vascular Disease Clinical Development, Bayer.
  • Effect of factor XIa inhibition with asundexian on recurrent ischemic stroke according to baseline patterns of infarction on brain MRI: PACIFIC-Stroke.6
    Khatri P, Shoamanesh A, Mundl H, et al.
  • Effects of the oral factor XIa inhibitor asundexian on intracranial bleeding among patients with acute non-cardioembolic ischemic stroke: PACIFIC-Stroke randomized trial.
  • 7